Zobrazeno 1 - 10
of 119
pro vyhledávání: ''
Autor:
Takeo Maekawa, Satoshi Fukushima, Taiki Isei, Takehiro Onuma, Naoya Yamazaki, Takashi Inozume, Natsuki Baba, Hiroshi Kato, Osamu Yamasaki, Yasuo Nakai, Yoshiyasu Umeda, Shusuke Yoshikawa, Kotaro Nagase, Taisuke Matsuya, Shigeto Matsushita, Atsushi Otsuka, Takahide Kaneko, Motoo Nomura, Masazumi Onishi, Yasuhiro Nakamura, Yutaka Kuwatsuka, Noriki Fujimoto, Kenjiro Namikawa, Tatsuya Takenouchi, Yukiko Kiniwa, Shintaro Saito, Ryo Tanaka
Publikováno v:
European journal of cancer (Oxford, England : 1990). 157
Background Immune checkpoint inhibitors (ICIs) have a lower efficacy in mucosal melanoma (MUM) than in cutaneous melanoma. The use of combination treatments with radiotherapy (RT) to improve the efficacy in MUM, however, requires further investigatio
Autor:
Jiazhi Mo, Zhihong Chi, Yan Kong, Huayan Xu, Rong Duan, Lu Si, Xieqiao Yan, Jun Guo, Xuan Wang, Caili Li, Lili Mao, Li Zhou, Jie Dai, Bin Lian, Bixia Tang, Siming Li, Xinan Sheng, Xue Bai, Chuanliang Cui
Publikováno v:
European journal of cancer (Oxford, England : 1990). 156
Purpose The combination of vascular endothelial growth factor receptor (VEGFR) inhibitor and programmed cell death-1 (PD-1) blockade provides promising therapeutic opportunities for advanced mucosal melanoma in early phase trials. The aim of this ret
Autor:
Carla M.L. van Herpen, Marie Vinches, Catherine Fortpied, Éva Remenár, Petr Szturz, Cyril Abdeddaim, John S. Stewart, Jan B. Vermorken
Publikováno v:
European Journal of Cancer, 156, 109-118
European Journal of Cancer, 156, pp. 109-118
European journal of cancer
European Journal of Cancer, 156, pp. 109-118
European journal of cancer
Contains fulltext : 238276.pdf (Publisher’s version ) (Closed access) BACKGROUND: In the TAX 323 (EORTC 24971) phase III trial enrolling patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN), the
Autor:
Chloe Khoo, Paolo A. Ascierto, Serigne Lo, Victoria Atkinson, Alexander M. Menzies, Helen Dearden, Douglas B. Johnson, Lewis Au, Matteo S. Carlino, Marcello Cuvietto, Lisa Zimmer, Georgina V. Long, Zeynep Eroglu, James Larkin, Jessica Smith, Shahneen Sandhu, Daniel Y. Wang
Publikováno v:
European journal of cancer (Oxford, England : 1990). 153
Background Combination ipilimumab and nivolumab is approved for several malignancies. Toxicity most often occurs 6–10 weeks into treatment. Whether very early toxicity is harder to manage or influences efficacy is unknown. Methods Consecutive metas
Autor:
Dirk Schadendorf, Carmen Loquai, Felix Kiecker, Konstantin Drexler, Laura Susok, Peter Mohr, Katharina C. Kähler, Leonie Bluhm, Lydia Reinhardt, Friedegund Meier, Jessica C. Hassel, Selma Ugurel, Claudia Pföhler, Sarah Knispel, Bastian Schilling, Christopher G. Cann, Simone M. Goldinger, Elisabeth Livingstone, Andreas Stang, Thomas Eigentler, Cindy Franklin, Julia K. Tietze, Maria Isabel Fleischer, Carola Berking, Paolo A. Ascierto, Judith Sirokay, Carsten Weishaupt, Patrick Schummer, Lisa Zimmer, Georgina V. Long, Maximilian Gassenmaier, Carina N. Owen, Lucie Heinzerling, Raphael R. Reinhard, Douglas B. Johnson, Kai Martin Thoms, Alexander M. Menzies, Dennis Niebel, Ralf Gutzmer
Publikováno v:
European journal of cancer (Oxford, England : 1990). 148
Background Elevated lactate dehydrogenase (LDH) is a known predictive and prognostic factor for a poor outcome in patients with metastatic melanoma. It is unclear whether first-line targeted therapy (TT) or immune checkpoint inhibition (ICI) is more
Autor:
Garrick Kassab, José Baselga, Alvaro Moreno-Aspitia, Otto Metzger Filho, Richard D. Gelber, David W. Hillman, Kamal S Saini, Christine Campbell, Ann E. McCullough, Larissa A. Korde, Antonio C. Wolff, Masakazu Toi, Kathleen I. Pritchard, Miguel Izquierdo, Zeba Aziz, Daniela Dornelles Rosa, Frances M. Boyle, Ian E. Smith, Celine Schurmans, Georgia Demetriou, István Láng, Michael Untch, Binghe Xu, Zhimin Shao, Eileen Holmes, Evandro de Azambuja, Carlos Barrios, Eleanor McFadden, Martin Andersson, Martine Piccart-Gebhart, Debora Fumagalli, Sung Hoon Sim, Robin McConnell, Christian Jackisch, Ajay O. Mehta, Sarra El-Abed, Vicki Paterson, Emma Paterson, Florentine Hilbers, Michael S. Ewer, Vasiliki Balta, Sebastien Guillaume
Publikováno v:
Eur J Cancer
Aim To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial. Patients and methods 8381 patients with stage I-III HER2 positive breast cancer randomised to chemotherapy plus 1-year of trastuzumab (T), oral lapatinib (L
Autor:
Valérie Boige, Milan Najdawi, Lambros Tselikas, Melodie Tazdait, Michel Ducreux, Maximiliano Gelli, Alice Boilève, Alicia Larive, Cristina Smolenschi, David Malka, Astrid De Cuyper, Jean-Pierre Pignon, Linda Mahjoubi
Publikováno v:
European journal of cancer (Oxford, England : 1990). 138
Background Hepatic arterial infusion (HAI) combined with systemic chemotherapy has shown promising results in patients with unresectable colorectal liver metastases (CRLM), even after failure to systemic therapy. Addition of systemic targeted therapi
Autor:
Mitsuro Kanda, Toshisada Aiba, Masamichi Hayashi, Naomi Hayashi, Takashi Kinoshita, Chie Tanaka, Mitsuru Sakai, Suguru Yamada, Goro Nakayama, Hiroyuki Yokoyama, Yusuke Sato, Michitaka Fujiwara, Kei Uehara, Kenta Murotani, Daisuke Kobayashi, Kiyoshi Ishigure, Yasuhiro Kodera, Hitoshi Teramoto, Kei Muro, Masanori Nakamura, Nao Takano, Shinichi Umeda, Norifumi Hattori, Yuichi Ando, Masahiko Koike, Akiharu Ishiyama, Masahiko Ando, Fuminori Sonohara, Hiroya Taniguchi, Ryoji Hashimoto
Publikováno v:
European journal of cancer (Oxford, England : 1990). 144
Peripheral sensory neuropathy (PSN) caused by oxaliplatin-based adjuvant chemotherapy adversely affects patients' quality of life. This study evaluated the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) with intermittent oxaliplatin use
Autor:
Lucia Del Mastro, Matteo Lambertini, Michelino De Laurentiis, Teresa Gamucci, Marco Bruzzone, Piero Fregatti, Sabino De Placido, Eva Blondeaux, Loredana Miglietta, Francesco Cognetti, Claudia Bighin, Gim investigators, Francesca Poggio, E. Valle, Benedetta Conte, Francesco Boccardo, Cecilia Nisticò, Fabio Puglisi, Barbara Cardinali, Filippo Montemurro, Ornella Garrone, Marcello Ceppi
Publikováno v:
European journal of cancer (Oxford, England : 1990). 136
Background: Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Ita
Autor:
Olivier Raffy, Adrien Dixmier, Gérard Zalcman, Clara Fontaine-Delaruelle, Damien Pouessel, Olivier Molinier, Sandrine Hiret, Franck Morin, Patrick-Aldo Renault, Julien Mazieres, Charles Dayen, Patrick Dumont, Catherine Becht, Sylvestre Le Moulec, Eric Pichon, Benjamin Besse, Clarisse Audigier-Valette, Claire Poulet, Fabrice Barlesi, Alexis B. Cortot, Denis Moro-Sibilot, Alexandra Langlais
Publikováno v:
European journal of cancer (Oxford, England : 1990). 131
Purpose Second-line chemotherapy regimens have demonstrated poor benefit after failure of platinum-based chemotherapy in advanced non-squamous non–small-cell lung cancer (nsNSCLC). Methods In this multicentre, open-label phase III trial, patients w